THE EFFECTS OF UPADACITINIB ON ULCERATIVE COLITIS SYMPTOM RESOLUTION AND FATIGUE NORMALIZATION IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 U-ACHIEVE AND U-ACCOMPLISH RESULTS

被引：0
|
作者：
D'Haens, Geert
Tran, Jacinda N.
Danese, Silvio
Rubin, David T.
Aoyama, Nobuo
Lugering, Andreas
Klaff, Justin
Xuan, Si
Ilo, Dapo
Gonzalez, Yuri Sanchez
Panes, Julian
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Tu1737
引用
收藏
页码：S1102 / S1103
页数：2
相关论文
共 50 条
  • [41] Benefits of high versus low dose upadacitinib as maintenance treatment in ulcerative colitis patients who were responders to 8-week induction with upadacitinib: Results from the U-ACHIEVE phase 3 maintenance trial
    Feagan, Brian
    Parkes, Gareth
    Juillerat, Pascal
    Gecse, Krisztina
    Yao, Xuan
    Zhou, Wen
    Deng, Huiwen
    Ilo, Dapo
    Gonzalez, Yuri Sanchez
    Higgins, Peter D. R.
    SWISS MEDICAL WEEKLY, 2023, 153 : 2S - 2S
  • [42] Effect of upadacitinib on patient-reported symptoms by the new Ulcerative Colitis Symptoms Questionnaire (UC-SQ) in patients with moderate to severe ulcerative colitis: data from the Phase 2b study U-ACHIEVE
    Ghosh, S.
    Aberra, F.
    Cross, R.
    Zhou, W.
    Chen, N.
    Lee, W. -J.
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S247 - S248
  • [43] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023, : 1479 - 1491
  • [44] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Chua, Laiyi
    Friedrich, Stuart
    Zhang, Xin Cindy
    CLINICAL PHARMACOKINETICS, 2023,
  • [45] Mirikizumab Pharmacokinetics in Patients with Moderately to Severely Active Ulcerative Colitis: Results from Phase III LUCENT Studies
    Laiyi Chua
    Stuart Friedrich
    Xin Cindy Zhang
    Clinical Pharmacokinetics, 2023, 62 (10) : 1479 - 1491
  • [46] Efficacy of Upadacitinib as an Induction Therapy in Severe and Refractory Ulcerative Colitis: Sub-Group Analysis of the Phase 2b Study U-ACHIEVE
    D'Haens, Geert R.
    Lindsay, James O.
    Loftus, Edward V., Jr.
    Zhou, Wen
    Cataldi, Fabio
    Xie, Wangang
    Pugatch, David
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S399 - S399
  • [47] Efficacy of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis by Biologic Inadequate Responder Status: Results From Two Randomized Phase 3 Studies
    Vermeire, Severine
    Tanida, Satoshi
    Hu, Renwei
    Panaccione, Remo
    Hebuterne, Xavier
    Rubin, David T.
    Ilo, Dapo
    Zhou, Wen
    Weinreich, Michael
    Zhou, Qing
    Danese, Silvio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S398 - S399
  • [48] CORTICOSTEROID-FREE REMISSION THROUGH 2 YEARS OF UPADACITINIB THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Dubinsky, Marla C.
    Atreya, Raja
    Abreu, Maria T.
    Nakase, Hiroshi
    Danese, Silvio
    Kujawski, Michelle
    Garrison, Andrew
    Eccleston, Jason
    Panaccione, Remo
    GASTROENTEROLOGY, 2024, 166 (05) : S812 - S813
  • [49] Corticosteroid-free remission through 2 years of upadacitinib therapy in patients with moderately to severely active ulcerative colitis
    Dubinsky, Marla
    Atreya, Raja
    Abreu, Maria
    Nakase, Hiroshi
    Danese, Silvio
    Kujawski, Michelle R.
    Garrison, Andrew
    Eccleston, Jason
    Smith, Rebecca
    Panaccione, Remo
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 164 - 164
  • [50] MAINTENANCE OF QUALITY OF LIFE IMPROVEMENT IN A PHASE 3 STUDY OF TOFACITINIB FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
    Panes, J.
    Rubin, D. T.
    Vermeire, S.
    Lindsay, J. O.
    Sands, B. E.
    Su, C.
    Friedman, G.
    Zhang, H.
    Kayhan, C.
    Manuchehri, A.
    Healey, P.
    GUT, 2017, 66 : A121 - A122
12345